Literature DB >> 8690773

Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks.

L D Dion1, J Fang, R I Garver.   

Abstract

The certification of recombinant adenoviruses prepared for clinical use requires the exclusion of contaminating, replication-competent adenovirus (wild type virus). Polymerase chain reaction (PCR)-based detection assays have been developed that detect the presence of viral sequences present only in wild type adenoviruses. As an alternative, this report describes a novel bioassay, designated the 'supernatant rescue assay', that detected minimal amounts of wild type virus mixed with high numbers of recombinant adenoviruses. This assay is based on the observation that minimal numbers of wild type adenovirus can be rescued from the supernatants of cells exposed to high multiplicities of infection (mois) of recombinant virus mixed with a known, minimal number of wild type virions. This assay was highly reproducible and routinely detected the presence of a single wild type virus mixed within 10(9) recombinant viruses. Under the experimental conditions employed, the supernatant rescue assay was significantly more sensitive than all three different PCR-detection assays.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690773     DOI: 10.1016/0166-0934(95)01973-1

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  21 in total

1.  Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases.

Authors:  C E Thomas; G Schiedner; S Kochanek; M G Castro; P R Löwenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

2.  Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction.

Authors:  M Puntel; J F Curtin; J M Zirger; A K M Muhammad; W Xiong; C Liu; J Hu; K M Kroeger; P Czer; S Sciascia; S Mondkar; P R Lowenstein; M G Castro
Journal:  Hum Gene Ther       Date:  2006-05       Impact factor: 5.695

3.  Adenoviral-mediated gene transfer into the canine brain in vivo.

Authors:  Marianela Candolfi; Kurt M Kroeger; G Elizabeth Pluhar; Josee Bergeron; Mariana Puntel; James F Curtin; Elizabeth A McNiel; Andrew B Freese; John R Ohlfest; Peter Moore; Pedro R Lowenstein; Maria G Castro
Journal:  Neurosurgery       Date:  2007-01       Impact factor: 4.654

4.  Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells.

Authors:  Carlos Barcia; Christian Gerdes; Wei-Dong Xiong; Clare E Thomas; Chunyan Liu; Kurt M Kroeger; Maria G Castro; Pedro R Lowenstein
Journal:  Neuron Glia Biol       Date:  2006-11

5.  Dynamic modulation of prohormone convertase 2 (PC2)-mediated precursor processing by 7B2 protein: preferential effect on glucagon synthesis.

Authors:  Michael Helwig; Sang-Nam Lee; Jae Ryoung Hwang; Akihiko Ozawa; Juan F Medrano; Iris Lindberg
Journal:  J Biol Chem       Date:  2011-10-19       Impact factor: 5.157

6.  Herpes simplex virus type 1 thymidine kinase sequence fused to the lacz gene increases levels of {beta}-galactosidase activity per genome of high-capacity but not first-generation adenoviral vectors in vitro and in vivo.

Authors:  M Puntel; R J Barrett; S Mondkar; V Saxena; K M Kroeger; A K M Muhammad; C Liu; N Bondale; S Sciascia; W Xiong; Y Shi; A Salem; A Zadmehr; P Huynh; D Palmer; P Ng; M G Castro; P R Lowenstein
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

7.  Neuronal expression of the transcription factor Gli1 using the Talpha1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease.

Authors:  D Suwelack; A Hurtado-Lorenzo; E Millan; V Gonzalez-Nicolini; K Wawrowsky; P R Lowenstein; M G Castro
Journal:  Gene Ther       Date:  2004-12       Impact factor: 5.250

8.  Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.

Authors:  Sumia Ali; Gwendalyn D King; James F Curtin; Marianela Candolfi; Weidong Xiong; Chunyan Liu; Mariana Puntel; Queng Cheng; Jesus Prieto; Antoni Ribas; Jerzy Kupiec-Weglinski; Nico van Rooijen; Hans Lassmann; Pedro R Lowenstein; Maria G Castro
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

9.  Differentiation and transcription factor gene therapy in experimental parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration.

Authors:  A Hurtado-Lorenzo; E Millan; V Gonzalez-Nicolini; D Suwelack; M G Castro; P R Lowenstein
Journal:  Mol Ther       Date:  2004-09       Impact factor: 11.454

10.  Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.

Authors:  Gwendalyn D King; Kurt M Kroeger; Catherine J Bresee; Marianela Candolfi; Chunyan Liu; Charlene M Manalo; A K M Ghulam Muhammad; Robert N Pechnick; Pedro R Lowenstein; Maria G Castro
Journal:  Mol Ther       Date:  2008-02-19       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.